Genfit SA is a French biopharmaceutical company that specializes in developing therapeutic solutions to tackle metabolic disorders and inflammatory diseases. The company was founded in 1999 in Lille, France, by Dr. Jean-Francois Mouney and a team of researchers from the Pasteur Institute and the European Genomics Institute for Diabetes.
Genfit's primary focus is on non-alcoholic steatohepatitis (NASH), a chronic liver disease that affects millions of people worldwide. The company's lead drug candidate, elafibranor, is a dual PPAR alpha/delta agonist that has shown promising results in clinical trials for NASH treatment. Genfit also has a pipeline of other drug candidates for metabolic disorders, including Type 2 diabetes and dyslipidemia.
In 2019, Genfit announced a strategic partnership with LabCorp to develop diagnostic tools for NASH, leveraging LabCorp's expertise in clinical laboratory testing and Genfit's expertise in NASH drug development.
However, in 2021, Genfit's elafibranor failed to meet the primary endpoint in a Phase 3 clinical trial for NASH treatment, causing a significant drop in the company's stock price. Despite this setback, Genfit remains committed to developing therapies for metabolic disorders and inflammatory diseases and continues to invest in its pipeline of drug candidates.
In addition to its drug development efforts, Genfit is also committed to advancing the understanding of NASH and raising awareness about the disease. The company sponsors research and education programs for NASH and collaborates with patient advocacy organizations to support patients and their families.